CytomX Therapeutics (NASDAQ: CTMX) reported Q2 EPS of $0.00, $0.06 better than the analyst estimate of ($0.06). Revenue for the quarter came in at $18.7 million versus the consensus estimate of $19.1 million.

For earnings history and earnings-related data on CytomX Therapeutics (CTMX) click here.